Svetlana A. Protsenko
Institute of Oncology NN Petrov · 126 works · 1,241 citations · h-index 12
Top works
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- [Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)].
- [Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer].
- BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment
- High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases
- [Preliminary results of the Russia (St.Petersburg)/WHO program for the evaluation of the effectiveness of breast self-examination].
- Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
- Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
- Vemurafenib-induced progression of breast cancer: a case report and review of the literature
- Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia
- IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE
- First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
- Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
- Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
- Final Results of Phase II Trial (MIRACULUM) of the Novel PD-1 Inhibitor Prolgolimab in Patients with Advanced Melanoma
- Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения
- Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma
- 1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study
- Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
- Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection